Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

Launched by FALO, LOUIS, MD · May 11, 2022

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment for cutaneous squamous cell carcinoma (cSCC), a type of skin cancer. The treatment involves using small patches with tiny needles that deliver a low dose of a chemotherapy drug called doxorubicin directly into the skin. The main goal of the study is to see how safe and effective these patches are for patients with this type of cancer. Researchers have previously determined that a dose of 50 micrograms is safe for use in another skin cancer type, and now they want to evaluate it specifically for cSCC.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of cSCC that can be surgically removed. They should not have any other active infections and must be in good overall health, meaning they can carry out daily activities without major limitations. Participants can expect to have their skin regularly checked where the patches are applied, and they will need to follow specific instructions from the research team. It’s important to note that this study is currently recruiting participants, and there are detailed eligibility criteria to ensure safety and effectiveness in the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects must have a histological diagnosis of cSCC based upon a skin biopsy.
• • 2. Subjects must have resectable stage I-III disease.
• • - Measures ≥5 millimeters (mm; post-biopsy) and \<100 mm in longest diameter
• • 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
• • 4. Subjects must have an expected survival of greater than or equal to 12 months.
• • 5. Subjects must not be on any other investigational device/drug treatment.
• • 6. Subjects must be willing to adhere to the instructions of the Investigator and his research team and sign an Informed Consent Form prior to entry into the study.
• • 7. Subjects must have the following pretreatment laboratory parameters: granulocytes ≥1,500/mm3; platelets \>50,000/mm3; serum creatinine ≤2X the upper limit of normal (ULN); AST, ALT ≤3X the ULN, bilirubin ≤1.5X ULN unless Gilbert's disease then ≤3X ULN.
• • 8. Subjects must be at least 18 years of age and must be able to understand the written informed consent/assent document.
• • 9. Subjects must have no evidence of active infection, regardless of the degree of severity or localization. Subjects with active infections (whether or not they require antibiotic therapy) may be eligible for study participation after complete resolution of the infection. Subjects on antibiotic therapy must be off antibiotics before beginning treatment.
• • 10. Subjects must not receive any other treatment for cSCC except emollients of subject's choice without topical steroids, anti-fungal or antibacterial topical preparations.
• • 11. Subjects with multiple cSCC may re-enroll in the study if greater than 4 weeks elapses between courses and if all other inclusion/exclusion criteria are met.
• • 12. Patients with HIV infection with CD4+ T-cell (CD4+) counts ≥ 350 cells/uL will be eligible for the study. Patients without a history of AIDS-defining opportunistic infections will be eligible for the study.
• • 13. Subjects must be willing/able to comply with standard of care measures for subjects with cSCC such as sun avoidance and sun protection.
• Exclusion Criteria:
• 1. Subjects with the following tumor characteristics:
• • \>4 mm depth;
• • Clark level IV;
• • perineural invasion, lymphovascular invasion;
• • primary site on the ear or non-glabrous lip;
• • location in the hands or feet;
• • large size: ≥10 mm on neck or pretibial area; ≥20 mm on trunk or extremities;
• • indistinct borders;
• • rapid growth;
• • recurrent lesion;
• • lesion in site of chronic inflammation or prior radiation therapy;
• • presence of neurologic symptoms; or • poorly differentiated, and aggressive histopathologic subtypes.
• • 2. Subjects with uncontrolled pain that would preclude participation in the study.
• • 3. Subjects who are pregnant or lactating.
• • 4. Subjects who have sensitivity to drugs that provide local anesthesia.
• 5. Impaired cardiac function or clinically significant cardiac disease, including any of the following:
• • Symptomatic congestive heart failure requiring treatment
• • Clinically significant cardiac arrhythmia
• • Uncontrolled hypertension
• • Corrected QT interval (QTc) \>470 msec at Screening or congenital long QT syndrome
• • Acute myocardial infarction or unstable angina pectoris \< 3 months prior to the first dose
• • New York Heart Association Functional Class III or higher (i.e. marked limitation of physical activity due to symptoms, or unable to carry on any physical activity without discomfort)
• • 6. Subjects with other active malignancies with the exception of non-metastatic prostate cancer and carcinoma in situ of the skin and cervix.
• • 7. Active, known, or suspected autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.
• • • Individuals with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, history of Hashimoto's thyroiditis on stable dose of thyroid hormone replacement therapy, adrenal insufficiency only requiring physiologic steroid replacement, or conditions not expected to recur should not be excluded.
• • 8. Major surgery within 2 weeks of the first dose of study agent
• • 9. History of or current drug-induced interstitial lung disease or pneumonitis Grade ≥2
• • 10. Subjects with the disease only on the face, skin folds, head, scalp, and genital area.